PRESS RELEASE published on 05/28/2024 at 19:00, 1 year 11 months ago JTC Team to Host the Virtual Investor Pitch Conference on June 17-18, 2024 JTC Team announces Virtual Investor Pitch Conference on June 17-18, 2024, featuring live video webcast presentations with Q&A. Participating company line-up to be revealed later Investor Relations JTC Team Virtual Investor Pitch Conference Live Video Webcast Q&A
BRIEF published on 05/23/2024 at 16:35, 1 year 11 months ago GRI Bio (NASDAQ : GRI) participe à Virtual Investor CEO Connect Relations Avec Les Investisseurs Communications D'entreprise Biographie Du GRI Investisseur Virtuel Connexion Du PDG
BRIEF published on 05/23/2024 at 16:35, 1 year 11 months ago GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect Investor Relations Corporate Communications GRI Bio Virtual Investor CEO Connect
PRESS RELEASE published on 05/23/2024 at 16:30, 1 year 11 months ago GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect JTC Team announces CEO Connect segment with GRI Bio's Marc Hertz, PhD, covering recent achievements and upcoming milestones. Virtual Investor platform offers more videos GRI Bio Virtual Investor CEO Connect JTC Team Communication Strategies
BRIEF published on 04/25/2024 at 15:50, 2 years ago Moleculin Biotech souligne le rôle de l'annamycine dans le traitement de la LMA dans le segment des investisseurs virtuels du JTC Essais Cliniques Opportunité D'investissement Biotechnologie Moléculaire Annamycine Traitement LMA
BRIEF published on 04/25/2024 at 15:50, 2 years ago Moleculin Biotech Emphasizes Annamycin's Role in AML Treatment in JTC Virtual Investor Segment Clinical Trials Investment Opportunity Moleculin Biotech Annamycin AML Treatment
PRESS RELEASE published on 04/25/2024 at 15:45, 2 years ago Moleculin Biotech (NASDAQ:MBRX) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team Moleculin CEO highlights Annamycin's differentiation in AML treatment landscape and investment opportunity. Positive interim data shared in 'What This Means' segment Investment Opportunity Clinical Trial Moleculin Biotech Annamycin AML Treatment
PRESS RELEASE published on 10/18/2023 at 16:00, 2 years 6 months ago JTC Team Announces Presenting Company Line Up for the Virtual Investor “Ask the CEO” Conference Being Held October 24-25, 2023
Published on 05/09/2026 at 01:30, 15 hours 58 minutes ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 17 hours 28 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 20:38, 20 hours 50 minutes ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 22 hours 15 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 22 hours 26 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 22 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 22 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 22 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 22 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 22 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
